Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients1
Authors:
- Takafumi KuzuyaTKTakafumi Kuzuya
- Takaaki KobayashiTKTakaaki Kobayashi
- Natsuko MoriyamaNMNatsuko Moriyama
- Takaharu NagasakaTNTakaharu Nagasaka
- Itsuo YokoyamaIYItsuo Yokoyama
- Kazuharu UchidaKUKazuharu Uchida
- Akimasa NakaoANAkimasa Nakao
- Toshitaka NabeshimaTNToshitaka Nabeshima
- 15 September 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Transplantation
- Vol. 76 (5) , 865-868
Abstract
Cyclosporine A (CsA) is a critical immunosuppressive drug with a narrow therapeutic range and wide interindividual variation in its pharmacokinetics. Many factors, including P-glycoprotein (PGP), influence the oral bioavailability and interpatient variability of CsA. A number of polymorphisms have been identified in the human MDR1 gene, and some of them have been found to be associated with an altered expression of PGP. We have investigated the role of these polymorphisms in CsA absorption from kidney transplant recipients. In addition, we also investigated the effect of amlodipine on CsA absorption. The area under the time-concentration curve from 0 to 2 hr (AUC0–2) estimated by the trapezoidal rule was used for the evaluation of extent of CsA absorption. The genotypes were identified by a polymerase chain reaction, restriction fragment length polymorphism analysis. No association was found between polymorphisms in the MDR1 and CsA AUC0–2/dose/kg. In contrast, the combination of amlodipine significantly increased CsA AUC0–2/dose/kg (706.2 μg·hr/L to 819.2 μg·hr/L, P <0.05). Furthermore, we attempted to compare MDR1 polymorphisms and the absorption of CsA again without patients receiving amlodipine, but there was still no significant difference. There is no relationship between polymorphisms for MDR1 and CsA absorption, suggesting polymorphisms for MDR1 cannot account for the interpatient variability of CsA. Amlodipine, which is the substrate of PGP, significantly increased CsA absorption. These results indicate that PGP plays a significant role in CsA absorption, but its polymorphisms could not influence the CsA absorption.Keywords
This publication has 22 references indexed in Scilit:
- MDR1 gene polymorphisms and disposition of the P‐glycoprotein substrate fexofenadineBritish Journal of Clinical Pharmacology, 2002
- Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjectsClinical Pharmacology & Therapeutics, 2002
- Identification of functionally variant MDR1 alleles among European Americans and African AmericansClinical Pharmacology & Therapeutics, 2001
- Active secretion and enterocytic drug metabolism barriers to drug absorption1PII of original article: S0169-409X(96)003304. The article was originally published in Advanced Drug Delivery Reviews 20 (1996) 99–112.1Advanced Drug Delivery Reviews, 2001
- Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivoProceedings of the National Academy of Sciences, 2000
- BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTERAnnual Review of Pharmacology and Toxicology, 1999
- Pharmacokinetics and Therapeutic Drug Monitoring of ImmunosuppressantsTherapeutic Drug Monitoring, 1995
- Reduced Inter- and Intraindividual Variability in Cyclosporine Pharmacokinetics from a Microemulsion FormulationJournal of Pharmaceutical Sciences, 1994
- BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTERAnnual Review of Biochemistry, 1993
- Pharmacokinetics of Digoxin and Main Metabolites/Derivatives in Healthy HumansTherapeutic Drug Monitoring, 1991